問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Colorectal Surgery

更新時間：2023-09-19

王煥昇
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王煥昇

List

15Cases

2013-07-31 - 2019-02-13

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2017-12-21 - 2020-04-01

Phase III

Active
A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Risankizumab(ABBV-066)

Participate Sites
6Sites

Recruiting5Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2016-10-10 - 2022-08-31

Phase III

Active
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
8Sites

Recruiting3Sites

Terminated3Sites

周仁偉
China Medical University Hospital-Taipei

未分科

林春吉
Taipei Veterans General Hospital

Division of Colorectal Surgery

2021-01-01 - 2026-03-31

Phase III

Completed
A Phase 3 Randomized Study of Lenvatinib in Combination With Pembrolizumab Versus Standard of Care in Participants With Metastatic Colorectal Cancer Who Have Received and Progressed On or After or Became Intolerant to Prior Treatment

  • Condition/Disease

    Metastatic Colorectal Cancer

  • Test Drug

    Pembrolizumab; Lenvatinib

Participate Sites
5Sites

Recruiting5Sites

2017-01-22 - 2023-12-22

Phase III

Active
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib

Participate Sites
13Sites

Recruiting9Sites

Terminated3Sites

邱正堂
Linkou Chang Gung Medical Foundation

2024-02-16 - 2027-06-08

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2013-07-31 - 2019-02-13

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2016-10-10 - 2022-08-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of ABT-494 for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis.

  • Condition/Disease

    Ulcerative colitis

  • Test Drug

    Upadacitinib(ABT-494)

Participate Sites
8Sites

Terminated6Sites

周仁偉
China Medical University Hospital-Taipei

未分科

林春吉
Taipei Veterans General Hospital

Division of Colorectal Surgery

2017-12-01 - 2020-04-01

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

  • Condition/Disease

    Crohn’s Disease

  • Test Drug

    Risankizumab(ABBV-066)

Participate Sites
6Sites

Terminated5Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2018-11-01 - 2021-03-30

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Evaluate the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Moderately to Severely Active Ulcerative Colitis

  • Condition/Disease

    Moderately to Severely Active Ulcerative Colitis

  • Test Drug

    Upadacitinib (ABT-494)

Participate Sites
6Sites

Recruiting2Sites

Terminated2Sites

周仁偉
China Medical University Hospital-Taipei

未分科

林春吉
Taipei Veterans General Hospital

Division of Colorectal Surgery

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB